Thrombolytic therapy for XXXX : a brief review.

@entity1 @entity697 @entity296 @entity63 @entity453 @entity583 @entity3479
Thrombolytic therapy given within the first 4 to 6 hours to @entity1 with evolving @entity697 appears to reduce in-hospital and 1-year mortality rates. In addition, @entity1 who receive treatment in the first few hours may also benefit through improved residual left ventricular function, resulting from the preservation of @entity63 myocardium. Newer agents that are more effective in lysing intracoronary thrombi are currently under development. The most promising is @entity3479 ( @entity3479 ), which is being evaluated in a number of large multicenter trials, including the National Heart, Lung, and Blood Institute's Thrombolysis in @entity583 (TIMI) trial. In this study researchers are also comparing the additional value of early versus delayed @entity453 and are evaluating a subset of @entity1 randomly assigned to early beta-blocker therapy to assess the value of adjunctive pharmacologic therapy. In the future, it is likely that studies will be carried out to determine the usefulness of thrombolytic therapy given to @entity1 by paramedics before hospitalization. Such a study is being planned in several communities. It is hoped that by means of prehospital therapy, it may be possible to treat a substantial group of @entity1 with symptoms and electrocardiographic findings of @entity697 before extensive left @entity296 has occurred. If this goal can be realized, it may be possible to achieve a very substantial reduction in mortality resulting from @entity697 . Initial experience with prehospital intravenous streptokinase therapy has already been reported from Jerusalem, Israel.(ABSTRACT TRUNCATED AT 250 WORDS)
